A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects With Hepatic Impairment and Control Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 22, 2015

Primary Completion Date

September 16, 2016

Study Completion Date

September 16, 2016

Conditions
HIV Infections
Interventions
DRUG

GSK1265744 30mg

GSK1265744 30mg tablets are white to almost white coated oval tablets. All subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by PK sampling.

Trial Locations (3)

32809

GSK Investigational Site, Orlando

55404

GSK Investigational Site, Minneapolis

80228

GSK Investigational Site, Lakewood

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY